共 157 条
[21]
Gonzalez R(1990)FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 Cancer Res 50 2009-3045
[22]
Grob JJ(1989)iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Int J Immunopharmacol 11 411-203
[23]
Cowey CL(2018)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Clin Cancer Res 24 3036-837
[24]
Lao CD(2016)Pharmacokinetics of recombinant interleukin 2 in humans Cancer Immunol Res 4 194-461
[25]
Motzer RJ(2016)Biodistribution and pharmacokinetics of recombinant, human Cancer Discov 6 827-1661
[26]
Escudier B(2019)I-interleukin-2 in mice Nat Med 25 454-1986
[27]
McDermott DF(2018)CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment Nat Med 24 1655-586
[28]
George S(2018)PD-1 blockade expands intratumoral memory T cells N Engl J Med 378 1976-1268
[29]
Hammers HJ(2017)Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade Immunity. 46 577-1858
[30]
Srinivas S(2016)A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Oncologist. 21 1260-519